UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Novel oral anticoagulants and reversal agents: Considerations for clinical development

The American heart journal, 2015-06, Vol.169 (6), p.751-757

2015

Volltextzugriff (PDF)

Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening To Prevent Strokes (mSToPS) trial

The American heart journal, 2016-05, Vol.175, p.77-85

2016

Volltextzugriff (PDF)

Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial

Contemporary clinical trials communications, 2019-06, Vol.14, p.100318-100318, Article 100318

2019

Volltextzugriff (PDF)

Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube

Clinical pharmacology in drug development, 2014-07, Vol.3 (4), p.321-327

2014

Volltextzugriff (PDF)

Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.42-55

2013

Volltextzugriff (PDF)

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1090

2004

Volltextzugriff (PDF)

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects

Journal of the American College of Cardiology, 2003-02, Vol.41 (4), p.557-564

2003

Volltextzugriff (PDF)

Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects

Thrombosis and haemostasis, 2002-02, Vol.87 (2), p.300

2002

Volltextzugriff (PDF)

Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion

Drug metabolism and disposition, 2006-05, Vol.34 (5), p.775

2006

Volltextzugriff (PDF)

Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model

Thrombosis and haemostasis, 2006-03, Vol.95 (3), p.447

2006

Volltextzugriff (PDF)

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin

The Journal of pharmacology and experimental therapeutics, 1998-01, Vol.284 (1), p.356

1998

Volltextzugriff (PDF)

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran

Clinical pharmacokinetics, 2003, Vol.42 (5), p.485-492

2003

Volltextzugriff (PDF)

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans

International journal of clinical pharmacology and therapeutics, 2012-08, Vol.50 (8), p.584

2012

Volltextzugriff (PDF)

Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor

The Journal of pharmacology and experimental therapeutics, 1999-05, Vol.289 (2), p.695

1999

Volltextzugriff (PDF)

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays

Thrombosis research, 2005, Vol.115 (1), p.9-18

2005

Volltextzugriff (PDF)

Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates

Thrombosis research, 2007-01, Vol.119 (1), p.121-127

2007

Volltextzugriff (PDF)

The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol

Journal of clinical pharmacology, 2004-04, Vol.44 (4), p.388-393

2004

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

European journal of clinical pharmacology, 2007-06, Vol.63 (6), p.571-581

2007

Volltextzugriff (PDF)

No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.935-941

2004

Volltextzugriff (PDF)

No Pharmacokinetic or Pharmacodynamic Interaction Between Atorvastatin and the Oral Direct Thrombin Inhibitor Ximelagatran

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.928-934

2004

Volltextzugriff (PDF)

The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma

Thrombosis research, 2004, Vol.113 (1), p.85-91

2004

Volltextzugriff (PDF)

Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects

Blood coagulation & fibrinolysis, 2003-07, Vol.14 (5), p.457-462

2003

Volltextzugriff (PDF)

A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor

Journal of clinical pharmacology, 2004-09, Vol.44 (9), p.1063-1071

2004

Volltextzugriff (PDF)

Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits

Archives of toxicology, 1996, Vol.70 (12), p.835-840

1996

Volltextzugriff (PDF)

Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation

Current medical research and opinion, 2004-03, Vol.20 (3), p.325-331

2004

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(26)
Male
(25)
Adult
(17)
Female
(15)
Pharmacology & Pharmacy
(15)
Benzylamines
(14)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Administration, Oral
(13)
Azetidines - Pharmacology
(13)
Pharmacology. Drug Treatments
(12)
Ximelagatran
(12)
Azetidines - Administration & Dosage
(11)
Azetidines - Pharmacokinetics
(11)
Thrombin - Antagonists & Inhibitors
(11)
Anticoagulants - Pharmacology
(9)
Animals
(8)
Anticoagulants - Administration & Dosage
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel oral anticoagulants and reversal agents: Considerations for clinical development

Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening To Prevent Strokes (mSToPS) trial

Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial

Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube

Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects

Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects

Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion

Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran

Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans

Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays

Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates

The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers

No Pharmacokinetic or Pharmacodynamic Interaction Between Atorvastatin and the Oral Direct Thrombin Inhibitor Ximelagatran

The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma

Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects

A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor

Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits

Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation

Suchergebnisse filtern